financetom
Business
financetom
/
Business
/
Becton Dickinson looks to separate life sciences unit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Becton Dickinson looks to separate life sciences unit
Feb 5, 2025 2:12 PM

Feb 5 (Reuters) - Becton Dickinson ( BDX ) said on

Wednesday its board has authorized a plan to separate its life

sciences unit as the medical device maker aims to focus on its

core business.

(Reporting by Kamal Choudhury, Christy Santhosh and Sriparna

Roy in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Becton Dickinson Fiscal Q1 Adjusted Earnings Fall, Revenue Rises; Shares Down Pre-Bell
Becton Dickinson Fiscal Q1 Adjusted Earnings Fall, Revenue Rises; Shares Down Pre-Bell
Mar 11, 2026
06:58 AM EST, 02/09/2026 (MT Newswires) -- Becton Dickinson ( BDX ) reported fiscal Q1 adjusted earnings Monday of $2.91 per diluted share, down from $3.43 a year earlier. Analysts polled by FactSet expected $2.81. Revenue for the quarter ended Dec. 31 was $5.25 billion, compared with $5.17 billion a year earlier. Analysts polled by FactSet expected $5.15 billion. The...
Apollo's fourth-quarter profit rises on strong inflows
Apollo's fourth-quarter profit rises on strong inflows
Mar 11, 2026
Feb 9 (Reuters) - Apollo Global Management ( APO ) reported a 13% rise in fourth-quarter profit on Monday, buoyed by inflows of fresh client money and strong debt origination. The New York-based alternative asset manager posted adjusted net income of $1.54 billion, or $2.47 per share, for the last ‌three months of the year. That compares with $1.36 billion,...
Lilly to acquire Orna Therapeutics to advance cell therapies
Lilly to acquire Orna Therapeutics to advance cell therapies
Mar 11, 2026
Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company ( LLY ) and Orna Therapeutics, Inc., a biotechnology company dedicated...
JOSS Realty REIT, Inc. Announces Launch of Initial Public Offering
JOSS Realty REIT, Inc. Announces Launch of Initial Public Offering
Mar 11, 2026
NEW YORK--(BUSINESS WIRE)-- JOSS Realty REIT, Inc. (JOSS or the Company) today announced the launch of its initial public offering of 3,000,000 shares of common stock. The initial public offering price is expected to be between $4 and $6 per share. JOSS expects to grant the underwriters a 45-day option to purchase up to an additional 450,000 shares of its...
Copyright 2023-2026 - www.financetom.com All Rights Reserved